Chemotherapy regimens in early breast cancer: major controversies and future outlook.
about
The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and TreatmentFirst-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancersMicro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigaInhibition of N-acetyltransferase 10 using remodelin attenuates doxorubicin resistance by reversing the epithelial-mesenchymal transition in breast cancer.
P2860
Chemotherapy regimens in early breast cancer: major controversies and future outlook.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Chemotherapy regimens in early breast cancer: major controversies and future outlook.
@en
type
label
Chemotherapy regimens in early breast cancer: major controversies and future outlook.
@en
prefLabel
Chemotherapy regimens in early breast cancer: major controversies and future outlook.
@en
P2860
P356
P1476
Chemotherapy regimens in early breast cancer: major controversies and future outlook.
@en
P2093
Beat Thürlimann
Markus Joerger
P2860
P304
P356
10.1586/ERA.12.172
P577
2013-02-01T00:00:00Z